SPAG5低表达与早期卵巢高级别浆液性癌患者预后关系
发布时间：2018-10-18 10:54
【摘要】：【目的】探讨SPAG5对卵巢高级别浆液性癌细胞生长及紫杉醇药物敏感性的影响,分析原发灶组织中表达水平差异与患者预后关系。【方法】体外实验中通过瞬时敲降卵巢腺癌细胞株中SPAG5,紫杉醇处理细胞后,MTT法检测细胞活力及绘制细胞生长曲线,研究SPAG5对细胞生长增殖及紫醇敏感性的影响;然后通过免疫组织化学染色,研究110例患者组织中SPAG5表达水平与患者预后的关系。【结果】SKOV3细胞中敲降SPAG5后发生细胞周期G2/M期阻滞,使细胞生长明显受抑;免疫组织化学染色显示,12例接受新辅助化疗患者肿瘤组织中SPGA5表达明显升高,对于未接受新辅助化疗患者,SPAG5低表达者疾病无进展生存较差,早期患者中差异更显著,患者总生存也有相似趋势,但差异无统计学意义;在卵巢腺癌细胞株OVCAR3 A2780及SKOV3中敲降SPAG5后,细胞对0.5μmol/L紫杉醇抵抗能力增强。【结论】SPAG5在卵巢腺癌细胞中调控细胞周期,促进细胞增殖,但早期卵巢高级别浆液性癌患者中SPAG5低表达者对紫杉醇的药物作用敏感性差,相应预后差,因此卵巢高级别浆液性癌辅助化疗方案应个体化选择。
[Abstract]:[objective] to investigate the effects of SPAG5 on the growth of ovarian high-grade serous cancer cells and the drug sensitivity of paclitaxel. To analyze the relationship between the expression level of primary tumor tissue and the prognosis of the patients. [methods] in vitro, SPAG5, paclitaxel was used to treat the ovarian adenocarcinoma cell line, and the cell viability and cell growth curve were measured by MTT method. To study the effect of SPAG5 on cell proliferation and the sensitivity of Violol, and then by immunohistochemical staining, To study the relationship between the expression level of SPAG5 and the prognosis of the patients. [results] after knocking down SPAG5 in SKOV3 cells, cell cycle G _ 2 / M phase arrest occurred and cell growth was significantly inhibited. Immunohistochemical staining showed that the expression of SPGA5 was significantly increased in tumor tissues of 12 patients with neoadjuvant chemotherapy. For patients without neoadjuvant chemotherapy, patients with low expression of SPAG5 had no progressive survival, and the difference was more significant in early patients. The total survival of the patients was similar, but the difference was not statistically significant. After knocking down SPAG5 in the ovarian adenocarcinoma cell line OVCAR3 A2780 and SKOV3, the resistance of the cells to 0.5 渭 mol/L paclitaxel was enhanced. [conclusion] SPAG5 regulates cell cycle in ovarian adenocarcinoma cells. Promote cell proliferation, but the low expression of SPAG5 in early ovarian high-grade serous carcinoma patients have poor sensitivity to paclitaxel and poor prognosis. Therefore, adjuvant chemotherapy regimen for ovarian high-grade serous carcinoma should be individualized.
【作者单位】： 中山大学附属第一医院妇产科;中山大学肿瘤防治中心妇科;
【基金】：广东省自然科学基金(2016A030310171)
【分类号】：R737.31
[Abstract]:[objective] to investigate the effects of SPAG5 on the growth of ovarian high-grade serous cancer cells and the drug sensitivity of paclitaxel. To analyze the relationship between the expression level of primary tumor tissue and the prognosis of the patients. [methods] in vitro, SPAG5, paclitaxel was used to treat the ovarian adenocarcinoma cell line, and the cell viability and cell growth curve were measured by MTT method. To study the effect of SPAG5 on cell proliferation and the sensitivity of Violol, and then by immunohistochemical staining, To study the relationship between the expression level of SPAG5 and the prognosis of the patients. [results] after knocking down SPAG5 in SKOV3 cells, cell cycle G _ 2 / M phase arrest occurred and cell growth was significantly inhibited. Immunohistochemical staining showed that the expression of SPGA5 was significantly increased in tumor tissues of 12 patients with neoadjuvant chemotherapy. For patients without neoadjuvant chemotherapy, patients with low expression of SPAG5 had no progressive survival, and the difference was more significant in early patients. The total survival of the patients was similar, but the difference was not statistically significant. After knocking down SPAG5 in the ovarian adenocarcinoma cell line OVCAR3 A2780 and SKOV3, the resistance of the cells to 0.5 渭 mol/L paclitaxel was enhanced. [conclusion] SPAG5 regulates cell cycle in ovarian adenocarcinoma cells. Promote cell proliferation, but the low expression of SPAG5 in early ovarian high-grade serous carcinoma patients have poor sensitivity to paclitaxel and poor prognosis. Therefore, adjuvant chemotherapy regimen for ovarian high-grade serous carcinoma should be individualized.
【作者单位】： 中山大学附属第一医院妇产科;中山大学肿瘤防治中心妇科;
【基金】：广东省自然科学基金(2016A030310171)
【分类号】：R737.31
【相似文献】
相关期刊论文 前10条
1 王波,张贵宇;卵巢外腹膜乳头状浆液性癌[J];国外医学.妇产科学分册;1995年02期
2 王苏荣,王波,李晓明;卵巢微乳头型浆液性癌的研究进展[J];中华妇产科杂志;2005年08期
3 孙e，
本文编号：2278904
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2278904.html
